Form 4: Disc Medicine CFO Executes Pre-Arranged Stock Sale Under 10b5-1 Plan

Disc Medicine, Inc.'s Chief Financial Officer, Jean M. Franchi, reported the sale of 2,000 shares of common stock for $57.5 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Jean M. Franchi, Chief Financial Officer of Disc Medicine, Inc. (IRON), reported the sale of 2,000 shares of the company's common stock.
• The transaction occurred on July 10, 2025, with shares sold at a price of $57.5 per share.
• Following this transaction, Jean M. Franchi beneficially owns 65,530 shares of Disc Medicine common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on March 10, 2025.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned insider sale, which is generally neutral to slightly negative. The fact it's under a 10b5-1 plan mitigates negative sentiment as it's not a discretionary sale based on new information.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled, non-discretionary sale rather than an immediate reaction to market conditions.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct equity stake in the company.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

This filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, potentially perceived as neutral to slightly negative, but mitigated by the pre-arranged nature of the 10b5-1 plan.

Key Dates

Keywords

Disc Medicine, IRON, SEC Form 4, Insider Trading, Stock Sale, Jean M. Franchi, Chief Financial Officer, Rule 10b5-1 Plan, Equity Transaction, Beneficial Ownership